АНЕМИЯ И ПРЕДДИАЛИЗНЫЕ СТАДИИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК: КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ, РАСПРОСТРАНЕННОСТЬ И ФАКТОРЫ РИСКА

хроническая болезнь почек, анемия, распространенность, факторы риска

1. Locatelli F, Valderrabano F, Hoenich N et al. Progress in dialysis technology: membrane selection and patient outcome. Nephrol Dial Transplant 2000; 15: 1133-1139

2. United States Renal Data System, 2002 Annual Data Report. Am J Kidney Dis 2003; 41(4) [suppl. 2]: s41-56

3. Nissenson AR, Pereira BJ, Collins AJ, Steinberg EP. Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization. Am J Kidney Dis 2001; 37(6):1177-1183

4. Obrador GT, Pereira BJ, Kausz AT. Chronic kidney disease in the United States: an underrecognized problem. Semin Nephrol 2002; 22(6): 441-448

5. Nickolas TL et al. Awareness of kidney disease in the US population: findings from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000. Am J Kidney Dis 2004; 44(2):185-197

6. McGill JB. Kidney Early Evaluation Program (KEEP). Findings from a community screening program. Diabetes Educ 2004; 30(2):196-198

7. Verhave JC et al. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int 2004; 66 (s92): S18-21

8. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41(1):1-12

9. Смирнов АВ, Добронравов ВА, Бодур-Ооржак АШ и др. Эпидемиология и факторы риска хронической болезни почек: региональный уровень общей проблемы. Тер архив 2005; в печати

10. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 [Suppl 3]:S112S119

11. Stevens LA, Levin A. Anaemia, cardiovascular disease and kidney disease: Integrating new knowledge in 2002. Curr Opin Nephrol Hypertens 2003;12(2):133138

12. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63(1):225-232

13. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial 2003;16(2):101-105

14. Manjunath G, Tighiouart H, Coresh J et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63(3):1121-1129

15. Mann JF, Gerstein HC, Pogue J et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134(8):629-636

16. Hillege HL, Fidler V, Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population Circulation 2002;106(14):1777-1782

17. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108(17):2154-2169

18. Go A, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. NEJM 2004; 351(13):1285-1295

19. Herzog CA, Puumala M, Collins AJ. NHANES III: The distribution of hemoglobin levels related to chronic kidney disease (CKD), diabetes (DM), and congestive heart failure (CHF). J Am Soc Nephrol 2002;13: 428A

20. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10(3):610619

21. McClellan WM, Flanders WD, Langston RD et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study. J Am Soc Nephrol 2002; 13(7):1928-1936

22. Parfrey PS, Foley RN, Harnett JD et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996; 11(7):12771285

23. Astor BC, Muntner P, Levin A et al. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (19881994). Arch Intern Med 2002; 162(12): 1401-1408

24. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002; 13(2): 504-510

25. Obrador GT, Roberts T, St. Peter WL et al. Trends in anemia at initiation of dialysis in the United States. Kidney Int 2001; 60(5):1875-1884

26. Obrador GT, Ruthazer R, Arora P et al. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 1999; 10(8):1793-1800

27. Jungers PY, Robino C, Choukroun G et al. Incidence of anaemia, and use of epoetin therapy in pre-dialysis patients: A prospective study in 403 patients. Nephrol Dial Transplant 2002; 17(9):1621-1627

28. Jurkovitz CT, Abramson JL, Vaccarino VL et al. Is the association between renal function and risk of developing coronary heart disease modified by hemoglobin status? Results from the Prospective Community-Based Atherosclerosis Risk in Communities (ARIC) study. J Am Soc Nephrol 2002;13: 434A

29. Collins AJ, Li S, St. Peter WL et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12(11):2465-2473

30. Keith D, Nichols G, Gullion C et al. Mortality of chronic kidney disease (CKD) in a large HMO population. J Am Soc Nephrol 2002;13: 620A

31. Foley RN, Parfrey PS, Harnett JD et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28(1):53-61

32. Harnett JD, Foley RN, Kent GM et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995;47(3):884-890

33. Silverberg D, Blum M, Peer G, Iaina A. Anemia during the predialysis period: A key to cardiac damage in renal failure. Nephron 1998; 80(1):1-5

34. London GM, Pannier B, Guerin AP et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 2001;12(12):2759-2767

35. Levin A, Thompson C, Ethier J et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999;34: 125-134

36. Gilbertson DT, Li SL, Murray A et al. The competing risks of death vs. ESRD in Medicare beneficiaries 65+with chronic kidney disease, CHF, and anemia. J Am Soc Nephrol 2002;13: 439A

37. Portoles J, Torralbo A, Martin P et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29: 541-548

38. Hayashi T, Suzuki A, Shoji T et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35: 250-256

39. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66(2):753-760

40. Deicher R, Horl WH. Anaemia as a risk factor for the progression of chronic kidney disease. Curr Opin Nephrol Hypertens 2003;12(2):139-143

41. Ueda H, Ishimura E, Shoji T et al. Factors affecting progression of renal failure in patients with type 2 diabetes. Diabetes Care 2003; 26(5):1530-1534

42. Iseki K, Ikemiya Y, Iseki C, Takishita S. Haematocrit and the risk of developing end-stage renal disease. Nephrol Dial Transplant 2003;18: 899-905

43. Keane WF, Brenner BM, De Zeeuw D et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy. The RENAAL Study. Kidney Int 2003; 63(4): 1499-1507

44. Cusick M et al. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26. Kidney Int 2004; 66(3):1173-1179

45. Jungers PY, Choukroun G, Oualim Z et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001;16(2): 307-312

46. Becker BN, Becker YT, Leverson GE, Heisey DM: Erythropoietin therapy may retard progression in chronic renal transplant dysfunction. Nephrol Dial Transplant 2002; 17(9): 1667-1673

47. Kuriyama S, Tomonari H, Yoshida H et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77(2):176-185

48. The US Recombinant Human Erythropoietin Predialysis Study Group: Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 1991;18(1):50-59

49. Krmar RT, Gretz N, Klare B et al. Renal function in predialysis children with chronic renal failure treated with erythropoietin. Pediatr Nephrol 1997;11(1):69-73

50. Clyne N, Jogestrand T. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 1992; 60(4):390-396

51. Eschbach JW, Kelly MR, Haley NR et al. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989;321(3):158-163

52. Smith RD, Schulman G et al.Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994;24(5):777-784

53. Lim VS, DeGowin RL, Zavala D et al. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 1989; 110(2): 108-114

54. Abraham PA, Opsahl JA, Rachael KM et al. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol 1990;10(2):128-136

55. Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int 2000;75: S22-S26

56. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000; 58(6): 2351-2366

57. Mazzali M, Jefferson JA, Vaziri ND, Johnson RJ. Microvascular and tubulointerstitial injury with chronic hypoxia induced-hypertension. J Am Soc Nephrol 2002;13: 328A

58. Rosenberger C, Mandriota S, Jurgensen JS et al. Expression of hypoxia-inducible factor-1alpha and-2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 2002; 13(7): 1721-1732

59. Denton KM, Shweta A, Anderson WP. Preglomerular and postglomerular resistance responses to different levels of sympathetic activation by hypoxia. J Am Soc Nephrol 2002; 13(1): 27-34

60. Strojek K, Grzeszczak W, Gorska J et al. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: Novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001;12(3): 602-605

61. Besarab A, Levin A. Defining a renal anemia management period. Am J Kidney Dis 2000; 36: S13-S23

62. Radtke HW, Claussner A, Erbes PM et al. Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. Blood 1979; 54: 877-884

63. Erslev AJ. Erythropoietin. N Engl J Med 1991; 324:1339-1344

64. Ross R, McCrea J, Besarab A. Erythropoietin response to blood loss in hemodialysis patients is blunted but preserved. ASAIO J 1994; 40: M880-M885

65. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989; 35:134-148

66. Mowry JA, Nissenson AR. Anemia. In: Massry SG, Glassock RJ., eds. Textbook of nephrology. 3d ed. Anemia, Williams & Wilkins, Baltimore, 1995; 1368-1373

67. Strauss MJ, Post FK, Somen C, Wolfe RA. An estimate of the size of the US predialysis population with renal insufficiency and anemia. Am J Kidney Dis 1993; 21:264-269

68. Kazmi W, Kausz A, Khan S et al. Anemia – an early complication of renal insufficiency. Am J Kidney Dis 2001; 38(4): 803-812

69. Milman N, Byg KE, Ovesen L et al. Iron status in Danish women, 1984-1994: a cohort comparison of changes in iron stores and the prevalence of iron deficiency and iron overload. Eur J Haematol 2003; 71(1): 51-61

70. Skjelbakken T, Langbakk B, Dahl IM, Lochen ML. Haemoglobin and anaemia in a gender perspective: The Tromso Study. Eur J Haematol 2005; 74(5): 381-388

71. El-Achkar TM, Ohmit SE, McCullough et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int 2005; 67(4):1483-1488

72. McClellan W, Aronoff SL, Bolton WK et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20(9):1501-1510

73. Bosman DR, Winkler AS, Marsden JT et al. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24(3): 495-499

74. Смирнов АВ, Каюков ИГ, Есаян АМ и др. Превентивный подход в современной нефрологии. Нефрология 2004; 8 (3): 7-14